General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0GMBZN
ADC Name
T-VCR 6b
Synonyms
T-VCR 6b
   Click to Show/Hide
Organization
Institut de Recherche de l'Ecole de Biotechnologie de Strasbourg.; Centre National de la Recherche Scientifique/Université de Strasbourg.
Drug Status
Investigative
Drug-to-Antibody Ratio
7.8
Structure
Antibody Name
Trastuzumab
 Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
 Antigen Info 
Payload Name
Vincristine (VCR)
 Payload Info 
Linker Name
Mc-Val-Cit-PABC
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.02&#1770.01
nM
CVCL_0033
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.02&#1770.01 nM High HER2 expression (HER2 +++)
Method Description
Cells were seeded in 96-well plates at a density of 2000 cells/well for MDA-MB-231 cells and 5 000 cells/well for all the other cell lines and allowed to grow under normal oxygen conditions (20% O2). Cells were treated with the appropriate compound 24 h after plating and maintained at 37 °C under a humidified 5% CO2 and 20% O2 atmosphere. Cell viability was measured 72 or 120 h later with the WST-1 cell proliferation assay (Takara) according to the manufacturer's instructions. To represent the relative cell proliferation rate, results were normalized against the untreated condition.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
References
Ref 1 Antibody-Vincristine Conjugates as Potent Anticancer Therapeutic Agents